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Abstract   Recent research has increasingly pointed to the importance of estrogens 
and the hypothalamic–pituitary–gonadal axis in schizophrenia. Specifically, there 
is mounting evidence from clinical, epidemiological and basic research that estra-
diol, the main component of estrogens, exerts protective effects in schizophrenia 
and related psychoses. Possible modes of action of this hormone in the brain have 
been suggested, and clinical intervention studies have reported the first positive 
results. Furthermore, there are an increasing number of reports on gonadal dys-
function and states of estrogen deficiency in women with schizophrenia. These 
findings could have important implications for clinicians and researchers alike. 
Keywords: estrogens, estradiol, schizophrenia, psychoses, gonadal function  
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1  Introduction 
Recent research increasingly points to the importance of estrogens and the hypo-
thalamic–pituitary–gonadal axis in schizophrenia and related psychoses.  
On the one hand there are reports of gonadal dysfunction and states of estrogen 
deficiency in women with schizophrenia (the hypothesis of hypoestrogenism). On 
the other hand there is mounting evidence from clinical as well as from epidemio-
logical and basic research that estradiol, the main component of estrogens, exerts 
protective effects in schizophrenia and related psychoses (the estrogen protection 
hypothesis) [1]. 
2  Estrogens: a protective factor in schizophrenia and related 
psychoses?  (The “Estrogen Protection Hypothesis”) 
2.1  Historical findings 
As long ago as at the beginning of the last century, psychiatrists recognized the 
possible association between schizophrenia and estrogens (for review see [1]). 
There are longstanding observations indicating an association between lowered es-
trogen blood levels and acute psychotic symptomatology. Early clinicians such as 
Kraepelin and Kretschmer described signs of chronic “hypoestrogenism” in wom-
en with schizophrenia. 
Kraft-Ebing was among the first to describe women becoming psychotic before 
or during menstruation, i.e. when blood levels of estrogen are relatively low. 
Kraepelin even created a separate diagnostic category, labelled “menstrual psy-
chosis”. Kretschmer reported cases where the outbreak of schizophrenia and relat-
ed psychoses had a temporal relationship with “surgery of ovaries, pregnancy, de-
livery and puerperium”. Finally, Manfred Bleuler noted that late-onset 
schizophrenia with onset after age 40 years was much more frequent in women 
than in men, a finding he attributed to the “loss of ovarian function” starting at 
around that age (for review, see [1]). 
2.2  Basic research findings  
Important findings from basic research were the identification of estrogen re-
ceptors in the limbic system of the brain, and the observation that the effects of es-
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trogens in rodents are, in some respects, similar to those of antipsychotic medica-
tions. Furthermore, it was shown that estrogens can modulate the sensitivity and 
number of dopamine receptors. It was therefore hypothesized that estrogens exert 
their antipsychotic effects in a manner similar to that of traditional antipsychotic 
medications at least partly by blockade of dopaminergic transmission [1]). 
We now know that estrogens, and especially 17-ß-estradiol (the natural estro-
gen that is most active in the brain), have many other neuroprotective and psycho-
protective effects. For example, they appear to improve cerebral blood flow and 
glucose metabolism, promote neuronal sprouting and myelination, enhance synap-
tic density and plasticity, facilitate neuronal connectivity, act as antioxidants, and 
inhibit neuronal cell death.  
Estrogens have also been shown to exert profound effects on brain differentia-
tion during development, particularly during late gestation and the early postnatal 
period, and are important in normal maintenance of brain function during ageing 
[2-5]. In a well controlled magnetic resonance imaging study, Goldstein et al. [3] 
showed that normal patterns of sexual brain dimorphism (brain regions found to 
be structurally different in normal men and women) are disrupted in schizophrenia 
and related psychoses, especially in the cortex. Apart from later ‘activational’ ef-
fects of circulating hormones (e.g. during puberty), those investigators suggested 
that these early ‘organizational’ effects of gonadal hormones that occur during the 
developmental period (which is probably critical for at least some forms of schiz-
ophrenia and related psychoses) could be partly responsible for that finding. 
The mechanisms of action of estrogens are now known not only to depend on 
the classical genomic pathway but also to involve nongenomic, rapid interactions, 
which explains the differing latency of effects. They clearly modulate the dopa-
minergic and other neurotransmitter systems that are believed to be relevant to 
schizophrenia and related psychoses, such as the serotonergic and glutamatergic 
system, but also the noradrenergic and cholinergic system (for reviews [2, 4, 6-9]. 
Recently it has even been suggested that 17-ß-estradiol in the brain might rather 
be regarded as a neurotransmitter itself than as a hormone [10]. 
There are at least two subtypes of estrogen receptors, namely estrogen receptor-
α and estrogen receptor-β, which are transcribed from two distinct genes [4]. Au-
topsy studies showed that estrogen receptor-α messenger RNA is expressed in 
discrete areas of the human brain such as the amygdala, hypothalamus, cerebral 
cortex and hippocampus; these areas are associated with neuroendocrine function, 
as well as emotion, memory and cognition [11].  
Recently Weickert et al. [12] reported a variation in the endogen receptor-α 
(ESR1) gene to be associated with schizophrenia and speculated that the mecha-
nism of this association may involve alternative gene regulation and transcript 
processing.  
Regarding the therapeutic effect of estrogens, it must also be noted that both 
the numerous direct effects on the brain and indirect effects may play a role. For 
example, estrogens may also increase blood levels of antipsychotic drugs via their 
actions on liver metabolism [13]. 
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2.3  Epidemiological findings  
Epidemiological studies into sex differences in schizophrenic disorders suggest 
that the physiologically high estradiol production in young fertile women contrib-
utes to the later age of onset of schizophrenia in women as compared with men, to 
the second peak of onsets in women around the menopause, and to the better 
course of the disease in young women [14-15]. Thus, in an epidemiological study 
on a representative sample of 392 first admitted patients with schizophrenia, the 
ABC Study, we found that schizophrenic women have a later peak of illness onset 
in comparison with schizophrenic men [16-18]. They also exhibit an additional, 
smaller peak after age 45. We postulated that estrogens raise the vulnerability 
threshold for the outbreak of the disease. According to this hypothesis, women 
would be protected against schizophrenia between puberty and menopause to 
some extent by their relatively high gonadal estrogen production during this time. 
Then, around age 45, several years before menopause sets in at a mean age of 51.4 
years, estrogen production begins to fall [19]. Thus women would lose the protec-
tion estrogens give, which could account for their second peak of illness onset af-
ter age 45. 
A number of risk factors appear to counteract the protective effect of estrogens. 
Thus, the sex difference in the age of onset diminishes in the subgroup of cases 
with a genetic risk and in patients with perinatal complications [20-21]. 
Recent results regarding the age of menarche further support the hypothesis 
that physiological estrogens play a protective role against the development of the 
disease. We demonstrated a significantly later age of menarche in a representative 
group of first admitted women with schizophrenia and related psychoses as com-
pared with a healthy control group [22]. Seeman and co-workers [23-24] found 
that later menarche was associated with an earlier onset of the illness, an associa-
tion that was independent of factors such as family history and obstetric complica-
tions.  
2.4  Clinical findings  
Clinically, psychotic symptomatology has often been found to correlate with 
the estrogenic state of women (for review [1, 25]. For example, during high estro-
gen phases such as pregnancy chronic psychoses appear to improve, whereas there 
is an excess of psychoses after delivery. 
Psychosis associated with estrogen withdrawal due to conditions other than the 
puerperium was recently reviewed by Mahé and Dumaine [26]. Those investiga-
tors reported cases of premenstrual psychosis, post abortion psychosis, and psy-
choses associated with removal of hydatiform mole, cessation of oral contracep-
tives, clomiphene and tamoxifen administration (both estrogen receptor 
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antagonists), and gonadorelin agonist administration (which blocks pituitary stim-
ulation of endogenous estrogen secretion). Psychotic episodes were acute, short 
and with a wide range of psychotic, but also affective, symptomatology. Recur-
rences were often reported when estrogen levels were normalized, and puerperal 
psychosis was frequent in the history of patients who were affected.  
Psychotic symptoms in schizophrenic patients have also often been shown to 
deteriorate premenstrually or perimenstrually (i.e. in the low estrogen phase of the 
cycle; for review [1, 22, 25]. Thus, Riecher-Rössler et al. [27-28] could show an 
inverse correlation of estradiol blood levels with psychopathology. They examined 
32 acutely admitted women with schizophrenia, who gave a history of regular 
menstrual cycles, and found a significant excess of admissions during the peri-
menstrual low estrogen phase of the cycle (p<0.005). During the hospital stay of 
the 32 women, there emerged a significant association between estradiol levels on 
the one hand and psychopathology scores on the other: Psychopathology seemed 
to improve when estradiol blood levels rose and vice versa. This was not only true 
for the total score of the Brief Psychiatric Rating Scale (BPRS [29]) and for al-
most all the subscores of this scale like anergia, thought disturbance, activation 
and hostile suspiciousness, but also for the general behaviour on ward as rated by 
the nurses (NOSIE [30]) and for general well-being and paranoid feelings as rated 
by the patients themselves (BfS and paranoid subscore of PDS, both by von Zers-
sen and Koeller [31]). 
Also, Bergemann et al. [32] found a significant effect of the menstrual cycle 
phase and 17-β-estradiol levels on positive and negative symptoms of 125 women 
with schizophrenia and related psychoses. The same authors [33] could further-
more show a significant effect of estrogen on the comprehension of metaphoric 
speech and/or concretism, a main feature of schizophrenic thought and language 
disturbance. Ko et al. [34] similarly found that 35 women with chronic schizo-
phrenia and related psychoses had low levels of estrogen which was associated 
with severe negative symptomatology and reduced cognitive functioning, espe-
cially in the domains of verbal performance and executive tasks.   
Most studies, however, did examine the direct correlation between psychosis 
symptomatology and estradiol serum levels directly. For example, a more recent 
study [35], reported behavioural, affective and somatic symptoms of schizophre-
nia (not psychotic ones) to be associated with the menstrual cycle phase. Estradiol 
was not measured. 
Rather than examining cyclic fluctuations, Hoff et al. [36] assessed the rela-
tionship between average estrogen levels from 4 consecutive weeks sampling with  
psychopathology and cognitive functioning in 22 female inpatients (aged between 
22 and 63 years) with chronic schizophrenia. There was no significant association 
between average estrogen levels and psychopathology, but higher average estro-
gen levels were strongly associated with better cognitive abilities. However, this 
finding may be due in part to the effects of ageing.  
It has to be noted that an elevated number of admissions during the perimen-
strual period has also been identified in other disorders [37], and exacerbation of 
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many psychiatric symptoms (not only psychotic ones) during the perimenstrual 
period was observed in patients with schizophrenia and related psychoses [27, 38]. 
In theory, this lack of specificity is to be expected because of the multiple effects 
of estrogen on mental functioning.  
Studies on gender differences conducted in the area of late-onset schizophrenia 
emphasise the significance of hormone changes related to the menopause. Reicher 
and colleagues [15, 22] showed that there are twice as many women as men with 
the onset of schizophrenia and related psychoses beyond 40 years of age, and that 
female patients with late onset illness suffered from unexpectedly severe disease 
in terms of symptomatology and course. One explanation for this could be the 
fluctuation and sharp decline in estrogen levels just before and during the meno-
pause. In support of this proposed explanation are results from long-term studies 
in women with schizophrenia showing that the course of illness in women tends to 
deteriorate rapidly during menopause and thereafter (for review [1, 39]. 
2.5  Intervention studies  
Intervention studies have also been conducted over long periods, mainly with 
positive results [40-41] (for review [1]). Thus, as early as the 1940s, Manfred 
Bleuler [42] reported the first unsystematic trials using a combination of ovarian 
and pituitary hormones. Mall [43], a German psychiatrist in charge of a large hos-
pital, examined 167 women suffering from schizophrenia with respect to estrogen 
excretion in 24-h urine samples, basal temperature and vaginal cytology. Based on 
his findings, he divided the psychoses into two groups: hypofollicular and hyper-
follicular. In the former group, he replaced estrogens and found that “hypofollicu-
lar psychosis can be healed relatively easily by this substitution therapy”. Unfor-
tunately, Mall does not give many details about these interesting studies.  
In the first systematic trial conducted in 1996, Kulkarni et al. [44] found that 
women with schizophrenia receiving estradiol as an adjunct to antipsychotic med-
ication treatment exhibited rapid and greater improvement in psychotic symptoms 
than women receiving antipsychotics alone. In 2001, the same group performed a 
double-blind, 28-day, placebo-controlled study [45] in which 12 women were ad-
ministered transdermal 17-ß-estradiol (patches) 50 microgram/24 h, another 12 
women received 100 microgram /24 h patches, and the third group received place-
bo patches. The 100 microgram group experienced greater improvement than ei-
ther the 50 microgram or placebo groups; with striking improvements observed in 
the key psychotic symptoms.  
In 2003, Akhondzadeh et al. [46] published a randomized study of  32 women 
of childbearing age with chronic schizophrenia. They administered ethinyl estra-
diol as an adjunct to haloperidol over 8 weeks while the control group received 
haloperidol only. The combination with estradiol showed a significant superiority 
over haloperidol alone regarding positive and negative symptom response. Fur-
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thermore, the estrogen group needed significantly less adjunctive anticholinergic 
medication to treat extrapyramidal side effects caused by haloperidol treatment. 
This finding is in line with other studies suggesting that estrogen treatment can al-
so reduce the severity of antipsychotic medication-induced extrapyramidal side ef-
fects ([47]).  
Louza et al. 2004 [48] did not find a positive response to estrogen treatment in 
their study, which they correctly discussed as possibly being due to having used 
conjugated estrogens rather than 17-ß-estradiol. In a Cochrane review in 2005, 
Chua et al. [49] surveyed data from only five randomised double blind interven-
tion studies with appropriate methodology. They concluded that the effects of es-
trogen as sole treatment or adjunctive therapy for those with schizophrenia and re-
lated psychoses were still unclear, but that further larger, clinical trials were 
needed. Studies in this review with negative results used conjugated estrogens and 
not 17-β-estradiol, although the latter has been shown to be the estrogen type with 
the most potent activity in the brain. Furthermore, in order to prevent endometrial 
hyperplasia, the estrogens were usually combined with progestogens which can 
counteract the positive effects of estradiol in the brain. 
Kulkarni et al. [50] recently conducted a proof-of-concept study of 102 women 
with DSM-IV schizophrenia. In this double-blind randomized controlled 28-day 
study, women received either an active 100 µg estradiol skin patch treatment 
(n=56) or an identical placebo patch (n=46). All patients received antipsychotic 
drug treatment according to a standardized protocol. Progesterone was not given 
during the study, hence the trial measured the impact of unopposed estradiol. Psy-
chopathology was assessed using the PANSS rating scale. Serum levels of estro-
gen, progesterone, prolactin, luteinising hormone, and follicle stimulating hor-
mone were measured. Several cognitive tests were also administered. They found 
that patients who received the 100 µg estradiol adjunct made a significantly better 
recovery in their total positive, negative, and general symptoms of schizophrenia 
than the patients who received standard antipsychotic medication only (P<0.01). 
Women who received the estradiol patch also showed significant improvement in 
cognition (P<0.01). By measuring luteinising hormone, they could also demon-
strate that there is a direct effect on the pituitary gland, which suggests that this 
dose and type of unconjugated estrogen directly affects the hypothalamic-
pituitary-gonadal axis.  
Overall, these studies provide strong evidence for the estrogen protection hy-
pothesis. The addition of transdermally delivered estradiol seems to be associated 
with significant abatement of psychotic symptoms in women with schizophrenia 
compared with standardized antipsychotic drug treatment alone. 
Most of the estrogen treatment studies conducted so far have been in young, 
reproductive age women and not in peri- or postmenopausal women with estrogen 
deficiency. Theoretically, the greatest effect of estradiol would be expected when 
it is replaced in a woman in a hypoestrogenic state. Good [51] conducted a study 
in postmenopausal patients. He administered estradiol and progesterone to 14 
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women with schizophrenia, schizophreniform disorder or schizoaffective disorder 
and found a significant improvement of negative symptoms over six months. 
There are also some case reports regarding positive results of hormone re-
placement therapy (HRT) in postmenopausal women with schizophrenia and re-
lated psychoses. Bergemann et al. [52] reported a case study of a woman with first 
onset of schizophrenia in the perimenopause period. The patient experienced se-
vere acute psychosis symptoms over several months, but refused antipsychotic 
treatment. As she was diagnosed to be in a periclimacteric state based on clinical 
symptoms and hormone analysis, she was started on transdermal estradiol in com-
bination with norethisterone acetate and had an impressive remission of the psy-
chotic symptoms. 
Lindamer [41] reported details about a postmenopausal woman, whose psy-
chotic symptoms improved with estradiol treatment as an adjunct to her antipsy-
chotic.  
In 2001, Lindamer and associates [53] studied a community sample of post-
menopausal women with schizophrenia and related psychoses. Twenty-four wom-
en received standard hormone replacement treatment (HRT), twenty-eight women 
had never received hormone treatment. Interestingly, the users of HRT needed a 
relatively lower average dose of antipsychotic medication and suffered fewer se-
vere negative symptoms. 
Ahokas et al. [54] described positive effects of estrogen treatment in women 
with postpartum psychosis. In those women who exhibited sustained estrogen de-
ficiency states, the addition of 17-ß-estradiol, without any further medication, 
yielded a dramatic antipsychotic effect within 1 week. However, the proportion of 
schizophrenia-like psychoses in the sample was not given. 
Finally, Kulkarni et al. [55] also tested the use of adjunctive estradiol in a small 
sample of 11 men with schizophrenia. They gave 2 mg oral estradiol valerate as an 
adjunct to six men who were taking antipsychotic drugs. Five men received oral 
placebo plus their standard antipsychotic medication for 7 days. This small study 
was only conducted for 7 days to avoid feminisation and other side effects in the 
men. The groups were matched for age, illness severity and duration. Oral, rather 
than transdermal, estradiol was used to ensure treatment adherence in men with 
acute psychosis. Psychopathology was assessed using the standardized rating 
scales, PANSS, and the Brief Psychiatric Rating Scale, BPRS. By day 5, the estra-
diol group showed significant abatement of psychotic symptoms compared with 
the placebo group and, by day 7, the estradiol group made further improvements. 
This study, although small in sample size and short in duration, raises the possibil-
ity that non-feminising estrogen may provide useful treatment possibilities for 
men with schizophrenia.  
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3  Hypo-estrogenism in women with schizophrenia (The 
hypothesis of hypoestrogenism) 
Several studies have recently confirmed earlier findings of disturbed gonadal 
function and hypo-estrogenism in women with schizophrenia [1, 27, 35, 39, 44, 
56-61]. They described menstrual irregularities and reduced blood levels of estra-
diol, progesterone and gonadotropins (follicle-stimulating hormone, luteinizing 
hormone) throughout the menstrual cycle, plus anovulation in the majority of 
women with schizophrenia and related psychoses. Reduced fertility was also re-
ported. 
There appear to be multiple reasons for these disturbances including the conse-
quences of emotional stress and/or antipsychotic medication induced hyperprolac-
tinaemia, which is known to suppress gonadal function [62]. However, these are 
probably not the only causes, because women experiencing other psychiatric dis-
orders with similar emotional stress do not have the same hypothalamic – pituitary 
– gonadal axis hormone changes, at least not to the same degree [39, 59]. Fur-
thermore, hypoestrogenism was observed long before the introduction of antipsy-
chotics.  
Smith et al. [60] found the dose of typical antipsychotics to correlate with pro-
lactin levels especially in women and prolactin to correlate inversely with estradi-
ol serum levels. In contrast to those findings, Huber et al. [59] were unable to 
identify a significant association of prolactin and estradiol in 43 women with acute 
psychosis, 14 women with other diagnoses and 9 healthy control women. Never-
theless, the women with schizophrenia and related psychoses had significantly 
lower estradiol serum levels than the control women. Women with other psychiat-
ric diagnoses fell in between the psychotic and the healthy group with regard to 
estradiol and prolactin levels. Also, Canuso et al. [57] found a high rate of ovarian 
dysfunction and estradiol levels below normal, irrespective of medication type or 
prolactin status in 16 premenopausal women with schizophrenia and schizoaffec-
tive disorders,. Interestingly, Warner et al. [63] found prolactin levels in unmedi-
cated schizophrenic patients to be even lower than in control individuals. Those 
investigators suggested that this was due to a disordered dopaminergic system be-
cause dopamine tonically inhibits prolactin. 
Taken together, these results imply that the hypothalamic–pituitary–gonadal 
axis is disturbed in many women with schizophrenia and related psychoses, and 
that the reasons for this are far from clear yet. An interesting research question in 
this context is whether gonadal dysfunction with estrogen deficiency could even 
be part of the underlying pathogenetic process, at least in a subgroup of women 
[22]. 
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4  Implications for clinicians and researchers 
Further research into the impact of gonadal function and estrogen on schizo-
phrenia and related psychoses is warranted because new diagnostic and therapeu-
tic strategies could emerge that would benefit the many women worldwide who 
suffer from this disorder. 
4.1  Assessment and therapy of gonadal dysfunction 
As there is growing evidence that many even younger women with schizophre-
nia and related psychoses are in a state of estrogen deficiency, in the future estro-
gens and the gonadal axis should be considered more seriously in the treatment of 
women with schizophrenia and related psychoses. Psychiatric history taking 
should always include questions regarding menstrual irregularities, amenorrhoea 
and galactorrhoea. Also, prolactin and estrogen serum levels should be tested, if 
necessary. Gonadal dysfunction and hypoestrogenic states can often be found even 
in menstruating women [27, 39, 60]. In addition, hyperprolactinaemia is clearly 
under-diagnosed [62]. Some authors have therefore suggested routine laboratory 
tests [60]. 
Most antipsychotics can cause hyperprolactinaemia and– especially if they are 
taken over a number of years – theoretically induce ‘iatrogenic early menopause’ 
via suppression of physiological estradiol production. The concomitant risks in-
clude both short-term effects, such as hot flushes and sexual dysfunction, as well 
as long-term consequences, including osteoporosis and potentially cardiovascular 
disease or cognitive deterioration [4, 62]. In patients with schizophrenia, these 
risks are further increased by additional risk factors such as smoking, poor diet 
and reduced exercise [60]. Furthermore, menopausal complaints may lead to com-
pliance problems.  
In the case of hyperprolactinaemia with secondary estrogen deficiency, prolac-
tin-sparing antipsychotics (e.g. clozapine, quetiapine, aripiprazole or maybe 
olanzapine [62] should therefore be preferred. If a switch to these antipsychotics is 
not possible for clinical reasons or if hypoestrogenism persists despite switching, 
then estrogen can be added to the treatment. Issues regarding contraception must 
be taken into account in such cases because, when switching to prolactin-sparing 
antipsychotics, the menstrual cycle often normalizes and fertility is regained, with 
high risk for unplanned pregnancy [64].  
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4.2  Estradiol as a therapeutic agent? 
First trials of estrogens in schizophrenia and related psychoses indicate that es-
tradiol could be used as an adjunct to antipsychotic medication. However, further 
replications of these findings in larger control studies by different groups are 
needed before recommendations for broad clinical application can be made. 
In women who suffer from frequent perimenstrual psychotic relapses, ‘cycle 
modulated’ antipsychotic medication therapy or, if contraception is needed at the 
same time, continuous use of oral contraceptives without hormone-free intervals 
may be strategies worthy of research [22, 65]. 
Even more promising could be hormonal replacement with estrogens in women 
with schizophrenia in peri- and postmenopause, because estrogens in other disor-
ders such as depression have proven to be especially helpful when they are used to 
restore hormonal balance. 
Hormonal replacement with estrogens for women with schizophrenia during 
and after the perimenopause could be recommended as an augmentation strategy 
respectively an adjunct to antipsychotic medication. Possibly, the dose of antipsy-
chotics could then be reduced and corresponding side-effects minimized. The re-
placement of estrogens in these women could also attenuate perimenopausal com-
plaints such as hot flushes, night sweats with sleep-disturbances and general 
irritability (see Table 11.1) which can contribute to a general deterioration of the 
mental state and, in vulnerable women, potentially provoke a psychotic episode. In 
contrast to this recommendation, it has been reported that women with schizo-
phrenia are less likely to ever use HRT as compared to women without psychiatric 
diagnoses [66]. 
Estrogen replacement therapy for women of this age group has been recom-
mended anyway for many reasons, for example prophylaxis of osteoporosis, and 
also delay of age-dependent cognitive deterioration or Alzheimer’s dementia [67] 
(for review see [68]; (Table 11.1). Further research into estrogen treatment as an 
additional indication in peri- and postmenopausal women with schizophrenia and 
related psychoses is urgently needed.  
 
Insert Table 11.1 here 
 
The use of estrogen has been questioned in the context of perimenopausal es-
trogen replacement by studies such as the WHI, Women’s Health Initiative Study 
[69], the WHI-M, Women’s Health Initiative Memory Study [70] and the HERS, 
Heart and Estrogen/Progestin Replacement Study [71]. These studies have high-
lighted the side effects of hormone replacement therapy which has provoked an 
ongoing controversy about the advantages and disadvantages of this regime. 
However, the WHI study has been criticised by many experts and by the Inter-
national Menopause Society [72] because of the advanced age of the study popula-
tion (mean age at inclusion was 63 years) who had a high prevalence of cardiovas-
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cular risk factors. Many of the complications noted for participants in the WHI 
study such as stroke, pulmonary embolism and myocardial infarction which were 
attributed to the vascular effects of estrogens, could well have been due to pre-
existing arteriosclerosis. 
The WHI conclusions have now been partially counteracted by a reanalysis 
[73], which showed that the cardiovascular complications can be reduced by using 
replacement therapy early in the perimenopause. This has opened a window of 
opportunity in which possibly even a cardiovascular benefit can be obtained in 
healthy menopausal women when replacement therapy is started early after the 
menopause (review [68]). 
Overall, the use of estrogens for therapeutic reasons must be distinguished 
from their preventative use. The WHI investigated the latter use and as described 
above, concerns about the conclusions have been made. The potential therapeutic 
use in women with psychosis or other mental disorders has been discussed here, 
and while care must be given to monitoring potential side –effects, the benefits for 
women with poor quality of life due to intractable schizophrenia often outweigh 
the risk of side- effects.  
Further research needs to be carried out into the best mode of HRT for psychi-
atric patients. To date, the natural 17-β-estradiol has been shown to have the best 
neuropsychoprotective effects compared with other estrogens that are often pre-
scribed. Transdermal application in the form of patches or gel is preferred because 
of smoother metabolism and potentially fewer side effects. Progestogens are usu-
ally added to estrogens in order to prevent endometrial cancer, but they can antag-
onize the positive effects of estrogens with respect to mental state [2, 65]. In addi-
tion, the systemic effects of progestogens can be minimized, potentially by other 
forms of application such as via an intrauterine device (IUD).  
Furthermore, alternatives to conventional HRT, i.e. compounds with more spe-
cific and potent estrogenic activity in the brain as opposed to other tissues, need to 
be investigated [22, 75]. Such compounds would both minimize the side effects of 
hormonal therapy and permit new therapeutic strategies in men. Possible candi-
dates are selective estrogen receptor modulators, which have agonistic or antago-
nistic properties that depend on the target tissue. However, the effects of the avail-
able selective estrogen receptor modulators on the brain remain to be clarified. 
Raloxifene, for example, appears to exert its main effects on the bone, although 
recent data suggest that it also acts on different brain receptors [70]. A recent 
study by Kulkarni et al  has shown promising antipsychotic effects for adjunctive 
raloxifene in postmenopausal women with schizophrenia [78]. Also, the synthetic 
steroid tibolone appears to cause less endometrial proliferation, but its effects on 
the central nervous system are still not clear, apart from the fact that it appears to 
have an androgenic effect and increases β-endorphin levels, with improvement in 
mood and libido [76]. Further studies on the brain-specific effects of selective es-
trogen receptor modulators and other estrogenic compounds (e.g. phyto-estrogens, 
xeno-estrogens and dihydroepiandrosterone) are urgently needed. 
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5.  Summary and conclusions 
In summary, there is emerging evidence that estrogens are very useful neuro-
protective and psychoprotective adjunctive therapies, which complement and en-
hance the traditional drug therapies for people with schizophrenia and related psy-
choses. However, it must be emphasized that the role for estrogen treatment 
strategies still requires further research. In particular, results from large, control 
studies are needed before estrogens may be recommended as adjunct therapy in 
standard clinical practice for the treatment of  women with schizophrenia , without 
proven estrogen deficiency. In contrast, other strategies should already be part of 
standard clinical care [77]. These include examination of the gonadal axis, with 
therapeutic actions, if indicated. The decision to use estrogen replacement therapy, 
must always be made on the basis of an individual risk–benefit assessment 
(NAMS 2000; Writing Group for the Women's Health Initiative Investigators 
2002) and in close collaboration with a gynaecologist. 
For future research, many questions remain unresolved, not only regarding new 
therapeutic strategies and compounds but also regarding the poorly understood 
disturbances of estrogens and the hypothalamic–pituitary–gonadal axis in women 
with schizophrenia and related psychoses. Further research in this area may sub-
stantially contribute to our understanding of the pathogenesis of this disease, at 
least in a subgroup of women. 
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Table 
11.1 
Some 
im-
portant 
effects 
of estro-
gen re-
place-
ment  
Positive Negative 
Perimenopausal complaints ↓ 
physical: hot flushes, genital discomfort, aging 
of collagen (skin, joints, intervertebral discs) ↓? 
mental: depression, irritability, emotional labil-
ity ↓ 
Endometrial carcinoma ↑ if unopposed es-
trogens are administered 
(→ in women without hysterectomy always 
combine with progestogens!) 
Risk of osteoporosis ↓ Risk of breast cancer ↑?  
(→ not in patients with a familiar or own risk 
and usually not longer than 7 years!) 
Delay of cognitive decline/Morbus Alzheimer? Risk of thrombosis and cerebral insult ↑?  
(→ no prescription for patients at risk!) 
Cardiovascular protection? 
(if started right after menopause) 
Other cardiovascular risks (coronary heart 
disease, arteriosclerosis) ↑?  
(→ start only within the first 10 years after 
menopause and not in patients with cardio-
vascular disease!) 
Sources: [68, 72-73] 
 
 
